Premium
REDUCE Trial Inspires Debate
Author(s) -
Kevin D. Blanchet
Publication year - 2009
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2009.08645.x
Subject(s) - citation , dutasteride , computer science , library science , prostate cancer , medicine , cancer
Washington University in St. Louis, Missouri, Dr. Andriole is having more than 15 minutes of fame. On the heels of publishing his results on the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial, he is once again in the spotlight. This time, it is for the findings from his Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial on the effect of dutasteride on prostate cancer risk reduction. The late-breaking presentation at the meeting was being debated even before Dr. Andriole stepped up to the microphone. In the REDUCE trial, dutasteride significantly lowered the risk of prostate cancer compared with placebo, with no increase in high-grade tumours. “The drug reduced the risk of prostate cancer over four years by 23%”, says Dr. Andriole, referring to the primary endpoint of the trial. “There were approximately 200 more cases of cancer occurring in men who took the placebo compared with men who took dutasteride”. During the four years, 83% of the 8200 participants had at least one biopsy; 22.5% of these had prostate cancer. Dr. Andriole is quick to point out that, “only a tiny minority of cancers was the result of the protocolindependent biopsy”. There was a 22.5% reduction in the Is dutasteride ready for widespread use as prevention for prostate cancer?